FINWIRES · TerminalLIVE
FINWIRES

Macy's Poised to Deliver In-Line Q2 Results With Limited Market Impact, UBS Securities Says

By

Macy's (M) is expected to deliver Q2 results broadly in line with expectations, with limited impact on investor sentiment, UBS Securities said in a note Wednesday.

The company is scheduled to report its Q2 earnings and sales results on Sept. 10.

UBS analysts said they raised their Q2 earnings per share forecast by $0.04 to $0.36, which is in line with consensus, and expect Macy's to raise its full-year 2026 EPS guidance to a range of $2.10 to $2.30, bracketing the Street's $2.23 consensus, as well as issue Q3 comp sales growth and EPS guidance in line with expectations.

Since the market appears to expect similar results, the investment firm said the report is not expected to significantly change sentiment or earnings estimates, leaving a balanced upside-downside outlook.

The options market is pricing in an 8% move around the report, compared with a 7.7% historical average, while analysts expect the actual move to be smaller than 8%.

Analysts said sentiment looks "bearish," with Macy's at 13.8% short interest, above its 5-year average and the Softlines industry average. The stock has also underperformed the S&P 500 by 960 basis points year to date, according to the note.

UBS Securities raised its price target on Macy's to $10 from $9, with a sell rating.

Price: $22.82, Change: $+0.23, Percent Change: +1.02%

Related Articles

Wire

Update: Worley Fiscal 2026 Underlying EPS, Aggregated Revenue Down; Shares Hit Six-Year Low

(Updates to add stock movement in the headline and the last paragraph.)Worley (ASX:WOR) logged AU$0.782 in underlying earnings per basic share for fiscal 2026, compared with AU$0.902 a year ago, a Wednesday filing showed.Analysts polled by FactSet expected AU$0.77.For the 12 months ended June 30, aggregated revenue was AU$12.02 billion versus AU$12.05 billion previously, the Australia-listed provider of engineering and project delivery services added. Analysts surveyed by FactSet projected AU$11.73 billion.The board proposed a final dividend of AU$0.25 per share, unchanged from a year earlier, payable Sept. 30 to shareholders of record as of Sept. 2.The company guided for fiscal 2027 underlying earnings before interest, taxes, and amortization growth, and for aggregated revenue growth, in the mid-to-high single-digit range.Its shares fell nearly 11% in recent trading on Wednesday and earlier hit their lowest since August 2020.

ASX:WOR
Wire

Update: HEICO Fiscal Q3 Earnings, Revenue Rise

(Updates to add share movement in the fifth paragraph.)HEICO (HEI) reported late Tuesday a fiscal Q3 earnings of $1.67 per diluted share, up from $1.26 a year earlier.Analysts polled by FactSet expected $1.51.Revenue for the quarter ended July 31 was $1.41 billion, up from $1.15 billion a year ago.Analysts expected $1.35 billion.Shares of the company rose 2.5% in after-hours trading.

$HEI
Wire

Spyre Halts Stand-Alone Rheumatoid Arthritis Drug Development; Shares Fall After Hours

Spyre Therapeutics (SYRE) said its experimental rheumatoid arthritis drug SPY072 failed to meet the company's internal performance threshold needed to justify further stand-alone development, prompting the halt of its monotherapy RA program.The drug delivered statistically significant improvements over placebo on several efficacy measures and showed a tolerable safety profile with no drug-related serious adverse events, the company said Tuesday in a statement.Spyre said it will now evaluate SPY072 in combination regimens and in other autoimmune indications, with additional clinical readouts expected in Q4.Spyre shares fell 12% in after-hours trading.

$SYRE